logo
welcome
CNBC

CNBC

Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar

CNBC
Summary
Nutrition label

73% Informative

Shares of Eli Lilly jumped more than 9% in premarket trading Thursday .

The company posted second-quarter revenue of $11.30 billion , up 36% from the same period a year ago .

The results come almost one week after the Food and Drug Administration said all doses of Zepbound and Mounjaro are available in the U.S ..

VR Score

81

Informative language

86

Neutral language

19

Article tone

formal

Language

English

Language complexity

41

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links